Literature DB >> 2147864

Down's syndrome and acute leukemia in children: an analysis of phenotype by use of monoclonal antibodies and electron microscopic platelet peroxidase reaction.

S Kojima1, T Matsuyama, T Sato, K Horibe, S Konishi, M Tsuchida, Y Hayashi, H Kigasawa, Y Akiyama, J Okamura.   

Abstract

The clinical, hematologic, and immunophenotypic features in 20 patients with Down's syndrome (DS) and acute leukemia were analyzed. Of the 20 patients, all 14 patients who were 3 years old and less were diagnosed as having acute megakaryoblastic leukemia (AMKL) by use of platelet-specific monoclonal antibodies and platelet peroxidase (PPO) reaction in electron microscopy. They were characterized by the presence of bone marrow fibrosis, having a history of myelodysplastic syndrome (MDS) and a poor response to chemotherapy. Only one patient has remained in continuous complete remission for more than 1 year. Acute leukemia in six patients who were older than 4 years was classified as common acute lymphoblastic leukemia antigen (CALLA)-positive acute lymphoblastic leukemia (ALL). In one of six patients classified as ALL, the leukemic blasts simultaneously expressed myeloid-associated surface antigens. All six patients achieved a complete remission and have remained in continuous complete remission and have remained in continuous complete remission from 10 to 52 months from the initial diagnosis. Although it has been suggested that the distribution of types of acute leukemia in patients with DS is similar to that in normal children, the present study shows that the distribution of acute leukemia types is quite different from that in patients without Down's syndrome.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2147864

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  4 in total

Review 1.  Prognosis and management of acute myeloid leukemia in patients with Down syndrome.

Authors:  J Timothy Caldwell; Yubin Ge; Jeffrey W Taub
Journal:  Expert Rev Hematol       Date:  2014-09-18       Impact factor: 2.929

2.  Distinctive multidrug sensitivity and outcome of acute erythroblastic and megakaryoblastic leukemia in children with Down syndrome.

Authors:  S Yamada; T Hongo; S Okada; C Watanabe; Y Fujii; H Hori; M Yazaki; R Hanada; Y Horikoshi
Journal:  Int J Hematol       Date:  2001-12       Impact factor: 2.490

3.  Lineage conversion from acute lymphoblastic leukemia to acute myeloid leukemia on rearrangement of the IgH gene in a patient with Down syndrome.

Authors:  Kazuya Tsuboi; Makoto Yazaki; Hiroshi Miwa; Shinsuke Iida; Shogo Banno; Atsushi Wakita; Masakazu Nitta; Ryuzo Ueda
Journal:  Int J Hematol       Date:  2002-07       Impact factor: 2.490

4.  Leukemia Risk in a Cohort of 3.9 Million Children with and without Down Syndrome.

Authors:  Emily C Marlow; Jonathan Ducore; Marilyn L Kwan; Stephanie Y Cheng; Erin J A Bowles; Robert T Greenlee; Jason D Pole; Alanna Kulchak Rahm; Natasha K Stout; Sheila Weinmann; Rebecca Smith-Bindman; Diana L Miglioretti
Journal:  J Pediatr       Date:  2021-03-06       Impact factor: 6.314

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.